Cover Image

A Bayesian joint model of multiple longitudinal and categorical outcomes with application to multiple myeloma using permutation-based variable importance

Fuente: arXiv

Saved in:

Bibliographic Details
Main Authors:	Alvares, Danilo, Barrett, Jessica K., Mercier, François, Schulze, Jochen, Yiu, Sean, Castro, Felipe, Roumpanis, Spyros, Zhu, Yajing
Format:	Preprint
Published:	2024
Subjects:	Methodology Applications
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A Bayesian joint model of multiple nonlinear longitudinal and competing risks outcomes for dynamic prediction in multiple myeloma: joint estimation and corrected two-stage approaches
by: Alvares, Danilo, et al.
Published: (2024)

Bridging the gap between two‐stage and joint models: The case of tumor growth inhibition and overall survival models
by: Danilo Alvares, et al.
Published: (2024)

Bayesian shared parameter joint models for heterogeneous populations
by: Chen, Sida, et al.
Published: (2024)

A new approach for Bayesian joint modeling of longitudinal and cure-survival outcomes using the defective Gompertz distribution
by: Neto, Dionisio Silva, et al.
Published: (2025)

The importance of autologous stem cell transplantation in improving outcomes in newly diagnosed patients with multiple myeloma
by: Morie A. Gertz
Published: (2024)

Bayesian semiparametric modelling of biomarker variability in joint models
by: Chen, Sida, et al.
Published: (2025)

Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application
by: Chloe Wylie, et al.
Published: (2025)

A Bayesian location-scale joint model for time-to-event and multivariate longitudinal data with association based on within-individual variability
by: Palma, Marco, et al.
Published: (2025)

CAR T‐cell therapy shows impressive outcomes for patients with refractory multiple myeloma
by: Mary Beth Nierengarten
Published: (2025)

Dysplastic plasma cells in multiple myeloma
by: Marco P. Barros Pinto
Published: (2025)

New standard of care for multiple myeloma?
by: Mary Beth Nierengarten
Published: (2024)

Accelerated approval of multiple myeloma therapies
by: Mary Beth Nierengarten
Published: (2024)

A joint spatiotemporal model for multiple longitudinal markers and competing events
by: Ortholand, Juliette, et al.
Published: (2025)

Medication‐related osteonecrosis of the jaw in an older patient with multiple myeloma
by: Larissa Couto de Freitas, et al.
Published: (2025)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
by: Danilo De Novellis, et al.
Published: (2024)

Navigating the evolving management of smoldering multiple myeloma
by: M. Bakri Hammami, et al.
Published: (2026)

Dynamic risk prediction model for multiple myeloma
by: Mary Beth Nierengarten
Published: (2024)

Are we there yet? CAR ‐T therapy in multiple myeloma
by: Eitan Mirvis, et al.
Published: (2024)

Mechanisms of resistance to daratumumab in patients with multiple myeloma
by: Katrine Fladeland Iversen
Published: (2024)

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities
by: Subhasree Kumar, et al.
Published: (2025)

Real‐world characteristics and outcomes of patients with multiple myeloma receiving second‐line treatment in England
by: Sally Moore, et al.
Published: (2024)

Accommodating informative visit times for analysing irregular longitudinal data: a sensitivity analysis approach with balancing weights estimators
by: Yiu, Sean, et al.
Published: (2023)

Bayesian clustering of multiple zero-inflated outcomes
by: Franzolini, Beatrice, et al.
Published: (2022)

Sequential multiple importance sampling for high-dimensional Bayesian inference
by: Binbin, Li, et al.
Published: (2025)

Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma
by: Rajshekhar Chakraborty, et al.
Published: (2024)

“Punched out” multiple myeloma lytic lesions in the skull
by: Vanessa Munhoz Bitelman
Published: (2016)

FDA approves first treatment for smoldering multiple myeloma
by: Leah Lawrence
Published: (2026)

BCL2 inhibition for multiple myeloma and AL amyloidosis
by: Lorenzo Cani, et al.
Published: (2025)

Cutaneous involvement in multiple myeloma. A rare entity
by: L. Rapparini, et al.
Published: (2025)

Teclistamab for relapsed refractory multiple myeloma patients on dialysis
by: P. Lebreton, et al.
Published: (2024)

Angiogenesis and multiple myeloma: Exploring prognostic potential of adrenomedullin
by: Angelos Giannakoulas, et al.
Published: (2024)

Correction to “Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma”
Published: (2024)

Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma
by: Ioannis V. Kostopoulos, et al.
Published: (2024)

Limits of Mahler measures in multiple variables
by: Brunault, François, et al.
Published: (2022)

Bayesian regularization for flexible baseline hazard functions in Cox survival models
by: Lázaro, Elena, et al.
Published: (2024)

Resumption of bone‐modifying agents in relapsed multiple myeloma does not improve outcomes: A real‐world analysis
by: Malcolm Su, et al.
Published: (2026)

Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations
by: Gayathri Ravi, et al.
Published: (2024)

High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
by: Veronica González‐Calle, et al.
Published: (2024)

Autologous stem cell transplantation for multiple myeloma patients whose myeloma‐defining event was SLiM
by: Iuliana Vaxman, et al.
Published: (2024)

Induction prior to autologous haematopoietic cell transplantation in multiple myeloma
by: Mohamad Mohty, et al.
Published: (2024)